Azacitidine (Onureg)
Small molecule
Also known as CC-486, BMS-986345
Evidence outlook
Approved: Acute Myeloid Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
VIALE-M NCT04102020 · Acute Myeloid Leukemia (AML) The study was nonrandomized, open-label, sequential, and had no comparator arm; its primary endpoint was dose-limiting toxicity during cycle 1, a safety measure assessed descriptively across dose groups. These design features do not allow a controlled comparison of treatment benefit, so the evidence is limited despite enrollment of 112 participants. Registry: NCT04102020 | 3 | Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1) (Up to 28 days (Cycle 1)); Number of Participants With DLTs of Venetoclax in Combination With Oral AZA (Part 3 Dose Finding Portion) (Up to 28 days (Cycle 1)) 2022-09-29 | Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1) (Up to 28 days (Cycle 1)): Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 — Neutropenia: 3 Participants; Leukopenia: 1 Participants; Thrombocytopenia: 1 Participants; Platelet count decreased: 1 Participants | Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 — Neutropenia: 4 Participants; Leukopenia: 0 Participants; Thrombocytopenia: 0 Participants; Platelet count decreased: 0 Participants | Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 — Neutropenia: 4 Participants; Leukopenia: 0 Participants; Thrombocytopenia: 0 Participants; Platelet count decreased: 0 Participants | Weak signal | link ↗ |
View 1 more trial
QUAZAR AML-001 NCT01757535 · Acute Myeloid Leukemia This was a randomized, quadruple-masked, placebo-controlled Phase 3 trial of 472 adults with acute myeloid leukemia in first remission after intensive chemotherapy. Its primary endpoint, overall survival, is a hard clinical endpoint that knowing the treatment cannot change, and oral azacitidine improved it (HR 0.69, p=0.0009). It is the basis of the US approval of Onureg for continued treatment in first remission. Source: ClinicalTrials.gov posted results. Registry: NCT01757535 | 3 | Kaplan-Meier (K-M) Estimate for Overall Survival (OS) (Day 1 (randomization) up to data cut off date of 15 July 2019; median follow-up for OS estimated by the reverse K-M method was 41.2 months for all participants.) 2019-07-15 | QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results). | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (1)
What this study did
Competitive landscape
Other DNMT1 (DNA methyltransferase 1) drugs
Azacitidine, Decitabine/Tetrahydrouridine (NDec). Compare all 3 DNMT1 (DNA methyltransferase 1) drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Azacitidine (Onureg): this drug | Approved | Small molecule | DNMT1 (DNA methyltransferase 1) | Weak signal | NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results). | |
| Decitabine / Cedazuridine (Inqovi) | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | Partial signal | Featured results are non-efficacy only in this race | |
| Enasidenib (Idhifa) | Approved | Small molecule | IDH2 | Partial signal | NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed | |
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | Partial signal | NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients. | |
| Gilteritinib | Approved | Small molecule | FLT3 | Partial signal | NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed | |
| Glasdegib | Approved | Small molecule | Hedgehog Pathway Inhibitor | Partial signal | No reviewed efficacy summary in this indication | |
| Ivosidenib (Tibsovo) | Approved | Small molecule | Mutant IDH1 | Reliable signal | NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis) | |
| Midostaurin (Rydapt) | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | Weak signal | NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results). | |
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | Weak signal | Featured results are safety only in this race | |
| Orca-T (TREGZI) | Approved | Cell therapy | Allogeneic engineered T-cell immunotherapy | Partial signal | NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5) | |
| Quizartinib | Approved | Small molecule | FLT3 | Reliable signal | NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2) | |
| Revumenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| Sargramostim (Leukine) | Approved | Protein / enzyme therapeutic | GM-CSF receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tretinoin (Vesanoid) | ApprovedUS marketing discontinued | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL | not yet graded | NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending | |
| Venetoclax | Approved | Small molecule | BCL-2 | Reliable signal | NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed | |
| Vyxeos | Approved | Small molecule | DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II | Partial signal | NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1). | |
| Ziftomenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| 131I-Apamistamab | Phase 3 | Monoclonal antibody | CD45 | Partial signal | NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001 | |
| Arsenic Trioxide (QTX-2101) | Phase 3 | Small molecule | PML-RARA fusion oncoprotein | not yet graded | No reviewed efficacy summary in this indication | |
| Arsenic Trioxide (SDK001) | Phase 3 | Small molecule | PML-RARA fusion oncoprotein | Partial signal | No reviewed efficacy summary in this indication | |
| Azacitidine | Phase 3 | Small molecule | DNMT1 (DNA methyltransferase 1) | Partial signal | NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed | |
| Bleximenib | Phase 3 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Clifutinib Besylate | Phase 3 | Small molecule | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Crenolanib | Phase 3 | Small molecule | FLT3 (including D835/ITD mutants), also PDGFR-alpha/beta | Reliable signal | NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145) | |
| Galinpepimut-S | Phase 3 | Vaccine | WT1 (Wilms Tumor-1 protein) | Weak signal | NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47% | |
| Lisaftoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mocravimod | Phase 3 | Small molecule | Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruserontinib | Phase 3 | Small molecule | FLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes) | Partial signal | No reviewed efficacy summary in this indication | |
| XY0206 | Phase 3 | Small molecule | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Annamycin | Phase 2/3 | Small molecule | Topoisomerase II (TOP2) | not yet graded | No reviewed efficacy summary in this indication | |
| BL-M11D1 | Phase 2/3 | Antibody–drug conjugate | CD33 | not yet graded | No reviewed efficacy summary in this indication | |
| Pivekimab Sunirine (Decnupaz) | Phase 2/3 | Antibody–drug conjugate | CD123 | not yet graded | No reviewed efficacy summary in this indication | |
| Cusatuzumab | Phase 2 | Monoclonal antibody | CD70 | Weak signal | NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38 | |
| Decitabine / Tetrahydrouridine (NDec) | Phase 2(overall) | Small molecule | DNMT1 (DNA methyltransferase 1) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Lintuzumab-Ac225 | Phase 2 | Radiopharmaceutical | CD33 | Weak signal | No reviewed efficacy summary in this indication | |
| Pegargiminase | Phase 2 | Protein / enzyme therapeutic | Arginine-depleting pegylated arginine deiminase | Weak signal | NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months | |
| Prexigebersen | Phase 2 | RNA / oligonucleotide | GRB2 (growth factor receptor-bound protein 2) mRNA | Weak signal | Featured results are safety only in this race | |
| Romaciclib | Phase 2 | Small molecule | CDK8 / CDK19 | Weak signal | NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response | |
| Sonrotoclax (Beqalzi) | Phase 2 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tagraxofusp | Phase 2 | Protein / enzyme therapeutic | CD123 | Weak signal | No reviewed efficacy summary in this indication | |
| Vididencel | Phase 2 | Vaccine | Allogeneic dendritic cell vaccine | Weak signal | NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported). | |
| AB8939 | Phase 1/2 | Small molecule | Tubulin | not yet graded | No reviewed efficacy summary in this indication | |
| ABD-3001 | Phase 1/2 | Small molecule | ALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1) | not yet graded | No reviewed efficacy summary in this indication | |
| Alrizomadlin | Phase 1/2 | Small molecule | MDM2 | Weak signal | No reviewed efficacy summary in this indication | |
| ARD103 | Phase 1/2 | Cell therapy | CLL-1 (CLEC12A) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD3632 | Phase 1/2 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Bexmarilimab | Phase 1/2 | Monoclonal antibody | Clever-1 | not yet graded | No reviewed efficacy summary in this indication | |
| BG1805 | Phase 1/2 | Cell therapy | CLL-1 (CLEC12A) | not yet graded | No reviewed efficacy summary in this indication | |
| BSB-1001 | Phase 1/2 | Cell therapy | HA-1 (minor histocompatibility antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| CART84 | Phase 1/2 | Cell therapy | CD84 | not yet graded | No reviewed efficacy summary in this indication | |
| CCTx-001 | Phase 1/2 | Cell therapy | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| CD123 Targeted CAR-NK Cells | Phase 1/2 | Cell therapy | CD123 | Weak signal | No reviewed efficacy summary in this indication | |
| CD123 / CD33 CART | Phase 1/2 | Cell therapy | CD123 / CD33 | not yet graded | No reviewed efficacy summary in this indication | |
| CLN-049 | Phase 1/2 | Multispecific antibody | FLT3, CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Debio 1562M | Phase 1/2 | Antibody–drug conjugate | CD37 | not yet graded | No reviewed efficacy summary in this indication | |
| Emavusertib | Phase 1/2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Enzomenib | Phase 1/2 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Ligufalimab | Phase 1/2 | Monoclonal antibody | CD47 | not yet graded | No reviewed efficacy summary in this indication | |
| Mobinitinib | Phase 1/2 | Small molecule | FLT3 / Aurora kinase A and B | not yet graded | No reviewed efficacy summary in this indication | |
| MRX-2843 | Phase 1/2 | Small molecule | Flt3/MerTK | Weak signal | No reviewed efficacy summary in this indication | |
| Ocifisertib | Phase 1/2 | Small molecule | PLK4 (Polo-like kinase 4) | Weak signal | Featured results are safety only in this race | |
| Olverembatinib | Phase 1/2 | Small molecule | BCR-ABL (also AKT, c-Kit, ERK) | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 62 furthest-along competitors are listed; 69 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Azacitidine (Onureg) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.